IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease
IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose and treat disease, has successfully brought its Series A to over $53 million (£40 million) in an oversubscribed financing round, co-led by IQ Capital and Molten Ventures, and supported by The British Business Bank and Meltwind alongside existing investors.
